The grant supports commercialisation of academic discoveries in health, which aligns with the venture's biotech focus. However, the applicant must be based in Nordic countries, while the venture targets EU (France) and UK, so geographic eligibility is a major constraint. The funding amount is modest but could support early validation if relocation or partnership were possible.